Newly Diagnosed?
We Can Help Getting the correct diagnosis and the most appropriate treatment from the start is crucial 
|
|
|
Great progress is being made in the treatment of gynecologic cancers, and Memorial Sloan-Kettering Cancer Center has been an integral part of that progress over the last several decades. Through the recruitment of outstanding young faculty in surgery, medical oncology, and laboratory research, we have become a major center for each of the major cancer types. Through our own research programs and those of the Gynecologic Oncology Group (GOG, a large cooperative cancer research initiative), we are committed to clinical research that will improve the survival and quality of life for women with gynecologic cancers.
Early Intervention
We believe that our most significant impact occurs when our resources are applied early in the cancer treatment program. Each year, the Gynecologic Disease Management Team treats more than 500 new patients with gynecologic cancers, more than 80 percent of whom are newly diagnosed.
Primary surgery at Memorial Sloan-Kettering allows our patients to benefit from the excellence and experience of our surgical staff. The group also has novel forms of chemotherapy available for those patients who have not yet started anticancer treatment.
A Premier Center for Treatment of GTD
Our Gynecologic Cancer Disease Management Team has one of the most sophisticated programs in the world for women with gestational trophoblastic disease, especially those whose disease is diagnosed at an advanced stage. Our treatment regimens are designed to deliver the most effective chemotherapy, using a combination of anticancer drugs to halt progression of cancer promptly and to avoid drug resistance.
With the appropriate treatment, even advanced gestational trophoblastic disease has a survival rate of more than 90 percent. Unfortunately, the low incidence of the disease means that few physicians have the experience and skill to treat such patients successfully. The management of advanced gestational trophoblastic disease is a highly specialized area, and treatment is best restricted to a handful of experienced centers nationally.
